Antiviral activity of digoxin and ouabain against SARS‐CoV‐2 infection and its implication for COVID‐19
The current coronavirus (COVID-19) pandemic is exacerbated by the absence of efective therapeutic agents. Notably, patients with COVID-19 and comorbidities such as hypertension and cardiac diseases have a higher mortality rate.An efcient strategy in response to this issue is repurposing drugs with a...
- Autores:
- Tipo de recurso:
- Article of investigation
- Fecha de publicación:
- 2020
- Institución:
- Universidad de Bogotá Jorge Tadeo Lozano
- Repositorio:
- Expeditio: repositorio UTadeo
- Idioma:
- eng
- OAI Identifier:
- oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/14400
- Acceso en línea:
- https://doi.org/10.1038/s41598-020-72879-7
http://hdl.handle.net/20.500.12010/14400
- Palabra clave:
- Antiviral activity
Digoxin
SARS‑CoV‑2
Infection
COVID‑19
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
- Rights
- License
- Abierto (Texto Completo)